Background The standard of care for neovascular age-related macular degeneration (nAMD) is repeated intravitreal injection ...

Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...

The Labour government is trying to reduce road deaths through its Road Safety Strategy, with cognitive and eyesight testing ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing "off the shelf" allogeneic cell therapies for serious medical conditions, today announced that 36-month results from ...

Six potential changes are being considered for drivers aged 70 and over as part of a Labour Party government consultation.

This Vision Health Month, Doctors of Optometry are reminding Albertans that clear vision is not the same as healthy eyes — ...

All 12 analysts covering the stock rate it a buy, with a mean price target of $37.17—implying 168% upside from Monday’s close of $13.85. Revenue estimates have risen 12% over the past 60 days, though ...

A phase III trial found that the sustained-release VEGF inhibitor implant OTX-TKI preserved visual acuity and retinal anatomy in wet age-related macular degeneration better than standard aflibercept ...

Safety signals with faricimab in routine practice, including intraocular inflammation and endophthalmitis, aligned with prior ...

Good baseline visual acuity retained in three-fourths of patients at 36 weeks with OTX-TKI ...

Wolters Kluwer, a global leader in professional information, software solutions and services, today announced the successful completion and full go?live of a two-phase platform for Segway-Ninebot, a ...

Lipid nanoparticles address key drug delivery challenges, including immune evasion, toxicity, and regulatory approval.